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Abstract
Blood transfusions are indicated for some acute complications of sickle cell disease (SCD). To
characterize the SCD population at increased risk of transfusion-associated complications, Geor-
gia hospital discharge data were used to estimate the frequency of intermittent transfusions and
the proportion of patients receiving them at multiple institutions. Ten years of data (2007-2016)
showed almost 19% of patients with SCD (1585/8529) received transfusions at more than one
hospital. The likelihood of multisite transfusions increased from ages 18 through 40 and with the
number of transfusions received. The results support the need to track and share transfusion his-
tories in order to reduce complication risks.
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1 INTRODUCTION
Many individuals with sickle cell disease (SCD) will develop acute
complications that require urgent transfusions, such as acute stroke,
acute chest syndrome, splenic or hepatic sequestration, aplastic cri-
sis, or multisystem organ failure. Chronic transfusions are used for
primary and secondary stroke prophylaxis, prevention of recurrent
splenic sequestration, and frequent pain episodes.1 Chronic transfu-
sions are typically administered in an outpatient setting at a single
center. Urgent transfusions may occur at multiple different sites over
time.2
Even with appropriate pretransfusion testing and iron chelation,
red blood cell (RBC) transfusions still carry risks of complications, such
as alloimmunization and iron overload. RBC alloimmunization is par-
ticularly problematic in SCD because it limits subsequent transfusion
options and can cause potentially fatal delayed hemolytic transfusion
Abbreviations: DHTR, delayed hemolytic transfusion reaction; ED, emergency department; REdHHoTT, Registry and Education for Hemovigilance in Hemoglobinopathy Transfusion Therapy;
SCD, sickle cell disease.
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reactions (DHTRs). The risk of DHTRs is more common in intermit-
tently transfused versus chronically transfused patients, and increases
when patients receive multiple transfusions.2–5 This could be related
to having incomplete transfusion histories available to transfusing
providers. Past studies show that a significant percentage of individ-
uals with serologically undetectable antibody titer due to evanescence
are transfused atmultiple health centers and at risk for DHTRs, hyper-
hemolysis, and further alloimmunization.2,6
Georgia is home to one of the largest SCDpopulations in theUnited
States—an estimated 7000-8500 of the 90000-120000 individuals
in the country with SCD.7,8 To characterize the SCD population at
increased risk of transfusion-associated complications, the Registry
and Education for Hemovigilance in Hemoglobinopathy Transfusion
Therapy (REdHHoTT) project in Georgia used hospital discharge data
to estimate the frequency of intermittent transfusions and the propor-
tion of patients receiving them atmultiple institutions.
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F IGURE 1 Patients with sickle cell disease (n=
8529) identified in hospital discharge data in
Georgia, 2007-2016, by the number of intermittent
transfusions and hospitals where>1 intermittent
transfusions were received
F IGURE 2 Multiply transfused patients with sickle cell disease (n= 3073) with single-site versus multisite intermittent transfusions, by
number of cumulative transfusions, 2007-2016
2 RESULTS
Using longitudinal data from Georgia’s Sickle Cell Data Collection
Program, we characterized the use of intermittent transfusions for
treatment of SCD in emergency departments (EDs) and inpatient set-
tings in Georgia from 2007 to 2016. Patients receiving outpatient
transfusions are not captured in this dataset as this analysis used hos-
pital discharge data (ED and inpatient data only). A transfusion was
defined as a single transfusion episode, regardless of the blood vol-
ume given. Individuals with SCD were defined as those who had three
or more encounters with an SCD diagnosis code during the study
period.9,10 Patient age was defined as of the date the first transfusion
was receivedduring the studyperiod.Basedonaprevious, unpublished
analysis of Georgia Medicaid claims data, inpatient and ED transfu-
sions represent about one-third of all SCD-related transfusions in the
state.
A total of 8529 unique patients with SCD were identified in Geor-
gia. Of these, 4584 (53.7%) had at least one ED or inpatient transfu-
sion, and more than two-thirds of these patients (n = 3073) received
multiple transfusions (Figure 1).
Fewer than half of patients with SCD who had multiple transfu-
sions received themall at the same hospital (1488/3073); nearly one in
five (589/3073) received transfusions at three ormore sites (Figure 1).
The likelihood of multisite transfusions increased with the total num-
ber of transfusions received (Figure 2); the Cochran-Armitage trend
test was significant, at P < .0001. While roughly one-third of the 798
patients who had exactly two intermittent transfusions over the 10
years received them at different hospitals, a vast majority of patients
(529/671, or 80%) who had 10 or more transfusions received them at
multiple sites. There was no significant difference in sex distribution
between patients who were multiply transfused at a single site (53%
female, 46.7% male) versus those who received multisite transfusions
(56.6% female, 43.4%male).
Out of the 1585 patients who had multisite transfusions, 175
patients (11%) were <10 years of age, 207 (13.1%) were 11-17, 471
(29.7%) were 18-25, 488 (30.8%) were 26-40, and 244 (15.4%) were
>40.
3 DISCUSSION
These findings show that almost one-fifth of patients within Geor-
gia receive intermittent transfusions at multiple hospital sites. Given
the lack of a statewide system to share patient transfusion histo-
ries across hospitals, this likely leads to increased risks of transfusion
complications such as RBC alloimmunization and DHTRs. Prior case
reports from Georgia have demonstrated the potentially fatal conse-
quences of patients receiving transfusions without their alloantibody
history being known.6 Additionally, most hospitals providing intermit-
tent transfusions topatientswithSCDdoso infrequently. Thougha few
Georgia hospitals are high-volume intermittent transfusion providers
for patients with SCD,many others average fewer than one SCD trans-
fusion per year.With limited experience, provider knowledge andprac-
tice may not be current with the latest evidence-based recommenda-
tions for transfusion in SCD.
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While 30% of patients who received multisite transfusions were
between 18 and 25 and presumably transitioning from pediatric to
adult facilities, the rate was similar in those who were 26-40, sug-
gesting age-related transition from pediatric to adult care was impor-
tant but not solely responsible for these findings. These results also
highlight the need to address alloantibody history during transition
planning.
Additionally, there was no significant difference in sex distribu-
tion between patients who were multiply transfused at a single insti-
tution versus those receiving multisite transfusions, suggesting that
pregnancy did not increase the risk of receiving multisite transfusions.
Some Georgia residents may also be intermittently receiving transfu-
sions outside of Georgia and out-of-state residents may be receiving
treatment within Georgia, so our results may actually underestimate
the extent of multisite transfusions.
We are unable to accurately determine the impact of transfusions
atmultiple centers on alloimmunization rates and frequency of DHTRs
due to retrospectiveuseof administrativedatasets. Futureprospective
studies should be considered to accurately characterize this risk.
The National Heart, Lung, and Blood Institute’s 2014 expert panel
report, Evidence-Based Management of Sickle Cell Disease, recommends
that patients with sickle cell receive blood with extended phenotypic
matching, including matching for C, E, and Kell antigens.11 The guid-
ance further advises that providers obtain an accurate transfusion his-
tory. British guidelines from2017state “a transfusionhistory shouldbe
obtained in all patients with SCD requiring transfusion, whether elec-
tive or emergency. Close communication is essential between clinical
and laboratory teams so that appropriate blood is given.”12 Failure to
follow these recommendations can result in formation of new alloanti-
bodies or reactivation of a previous one—even ones thatmay no longer
be serologically detectable—resulting in a potentially lethal DHTR.2–4
Previous studies show that a centralized regional or statewide
transfusion database can enhance transfusion safety, but privacy
issues have limited the establishment of a national database.2,3 The
REdHHoTT project is assessing the feasibility of implementing a trans-
fusion data registry using software applications designed to interface
with hospital blood bank data systems, retrieve select patient data,
and store them in a provider-accessible database. Antibody cards are
known to prevent potential DHTRs, but they are not standard prac-
tice at all hospitals.13 REdHHoTT is also developing a campaign to
inform patients about the need to carry transfusion history informa-
tion. This is being proposed using personalized approaches such as
physical cards, smartphone health data apps, or photographs of blood
bags and medical charts, and other technologies. Prospective studies
that include the cost and benefit analysis of preventive approaches are
required to determine the impact on DHTR and alloimmunization.
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